Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Avalo Therapeutics Inc. buy BTIG Research

Start price
€0.041
30.09.25 / 50%
Target price
€34.13
30.09.26
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 30.09.26. The prediction end date can be changed by BTIG_Research at any time.
Performance without dividends (%)
Name 1w 1m
Avalo Therapeutics Inc. - -
iShares Core DAX® -1.212% 1.925%
iShares Nasdaq 100 -4.714% -1.810%
iShares Nikkei 225® -2.976% -2.660%
iShares S&P 500 -2.744% -0.448%

Comments by BTIG_Research for this prediction

In the thread Avalo Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -
Target price 34.128
Change
Ends at 30.09.26

Avalo Therapeutics (NASDAQ:AVTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $40.00 price target on the stock.
Ratings data for AVTX provided by MarketBeat

Stopped prediction by BTIG_Research for Avalo Therapeutics Inc.

buy
Avalo Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.041
19.12.24
€38.45
19.12.25
-
28.12.23